Rethinking phase III trials in retinal biosimilars: Do we still need them?

Eye 2026 Open access

Read full text

Authors: Ashish Sharma, Baruch D. Kuppermann

DOI: 10.1038/s41433-026-04480-7

Cited by: 1

References: 6

Fields of Study & Subjects

Retinal Diseases and Treatments Drug-Induced Ocular Toxicity Biosimilars and Bioanalytical Methods

References 6